We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

7272:TSEYamaha Motor Co., Ltd. Analysis

Data as of 2026-07-10 - not real-time

¥1,239.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Yamaha Motor (7272.T) trades at a trailing P/E of roughly 7.7× and a forward P/E under 7×, placing it well below the sector average and suggesting the stock is undervalued relative to earnings. The company delivers a solid dividend yield of about 4 % with a modest payout ratio of 22 %, indicating that the dividend is sustainable given the strong operating cash flow of over ¥190 bn. Revenue is expanding at a healthy 16 % year‑over‑year, driven by both its traditional motorcycle and marine businesses and a new push into laboratory automation, highlighted by the recent partnership with Nikon for the CELL HANDLER 2 system. Despite a high debt‑to‑equity ratio near 100 %, the balance sheet is cushioned by ¥437 bn of cash and a manageable free‑cash‑flow stream.
Technically, the price sits above its 20‑day and 50‑day SMAs and is comfortably above the 200‑day SMA, confirming a bullish trend. RSI hovers around the neutral 50‑point mark, while the MACD histogram has turned slightly negative, suggesting a short‑term caution but not a reversal. Volume has been tapering and 30‑day volatility is around 25 %, implying moderate price swings. Recent market sentiment is exuberant (Fear‑Greed Index in “Extreme Greed”) and analysts project a modest upside of roughly 3 % with a median target near ¥1,275. Together, these fundamentals and technical cues support a hold stance in the near term, a buy outlook over the medium horizon, and a cautious hold for the long run.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above key moving averages confirming bullish trend
  • MACD histogram negative indicating short‑term caution
  • Attractive dividend yield with low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and entry into biotech automation
  • Low valuation multiples (P/E, P/B, P/S) relative to peers
  • Sustainable dividend and solid operating cash flow

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage offset by sizable cash reserves
  • Cyclical exposure of consumer‑cyclical auto segment
  • Stable but modest profitability (ROE, ROA) and modest free cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth16.60%
Profit Margin1.01%
P/E Ratio7.7
ROE3.84%
ROA2.70%
Debt/Equity98.20
P/B Ratio1.0
Op. Cash Flow¥192.3B
Free Cash Flow¥18.5B

Technical Analysis

TrendBullish
RSI50.7
Support¥1,206.50
Resistance¥1,287.00
MA 20¥1,237.90
MA 50¥1,221.93
MA 200¥1,166.35
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Target Price¥1,276.00
Upside/Downside2.99%
GradeUndervalued
TypeBlend
Dividend Yield4.06%

Risk Assessment

Beta-0.02
Volatility25.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.